Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Eyes Five Global Regions For Permanent Outposts

This article was originally published in PharmAsia News

Executive Summary

U.S. FDA is in the early stages of developing "boots on the ground" programs in five regions overseas in an effort to improve the quality of imported products at their source, Commissioner Andrew von Eschenbach said Jan. 24 at a media briefing on food safety issues

You may also be interested in...



Former FDA Commissioner Andrew von Eschenbach: An Interview With PharmAsia News (Part 2 of 2)

Von Eschenbach spoke with PharmAsia News about international regulatory collaboration and his vision for the future of the agency.

Former FDA Commissioner Andrew von Eschenbach: An Interview With PharmAsia News (Part 2 of 2)

Von Eschenbach spoke with PharmAsia News about international regulatory collaboration and his vision for the future of the agency.

U.S. FDA Move “Beyond Our Borders” Begins With China

Congressional concerns over inspection oversight in the midst of a heparin safety scare have not dampened FDA's efforts to highlight its new overseas initiative, "FDA Beyond Our Borders.

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel